• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Update: Annual Changes to the Nasdaq-100® Index

    12/12/23 6:00:00 PM ET
    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Investment Bankers/Brokers/Service
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NDAQ alert in real time by email

    NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023.

    The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same.

    Information

    For information about the company being added to the Nasdaq-100 Index® per this update, please visit the company website: Take-Two Interactive Software, Inc. – https://www.take2games.com/.

    About Nasdaq Global Indexes

    Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Nasdaq Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic, and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The Nasdaq OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -

    Media Relations ContactsInvestor Relations Contact  
    Name: Camille StaffordName: Index Client Services  
    Email: [email protected]

    Email  [email protected]  
      
    Name: Jennifer Lawson 
    Email: [email protected] 
      


    Primary Logo

    Get the next $NDAQ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NDAQ
    $PFE
    $SGEN
    $TTWO

    CompanyDatePrice TargetRatingAnalyst
    Take-Two Interactive Software Inc.
    $TTWO
    7/28/2025$265.00Overweight
    Wells Fargo
    Nasdaq Inc.
    $NDAQ
    7/25/2025$115.00Neutral → Buy
    UBS
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    Nasdaq Inc.
    $NDAQ
    4/8/2025$74.00Overweight → Equal-Weight
    Morgan Stanley
    Take-Two Interactive Software Inc.
    $TTWO
    2/19/2025$250.00Buy
    DA Davidson
    Take-Two Interactive Software Inc.
    $TTWO
    1/27/2025$175.00 → $230.00Buy → Neutral
    UBS
    Take-Two Interactive Software Inc.
    $TTWO
    1/27/2025$175.00 → $230.00Neutral → Buy
    UBS
    More analyst ratings

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Nasdaq Inc.

    SCHEDULE 13G/A - NASDAQ, INC. (0001120193) (Subject)

    8/12/25 10:34:26 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 13F-HR filed by Pfizer Inc.

    13F-HR - PFIZER INC (0000078003) (Filer)

    8/11/25 5:08:12 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Take-Two Interactive Software Inc.

    10-Q - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Filer)

    8/7/25 4:47:54 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    8/19/25 3:03:48 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dornemann Michael was granted 254 shares, increasing direct ownership by 1% to 21,948 units (SEC Form 4)

    4 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Issuer)

    8/18/25 4:32:50 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Director Moses Jon J was granted 254 shares and sold $231,330 worth of shares (1,000 units at $231.33), decreasing direct ownership by 3% to 22,901 units (SEC Form 4)

    4 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Issuer)

    8/18/25 4:31:24 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Your Poker Crew Just Got Bigger: Zynga Poker Launches on Steam

    Iconic mobile powerhouse now offers poker fans a new way to play as Zynga's first title to launch on the world's largest PC gaming platform from Valve Zynga Inc., a wholly-owned publishing label of Take-Two Interactive Software, Inc. (NASDAQ:TTWO) and a global leader in interactive entertainment, today announced that Zynga Poker, one of the largest and longest-running, free-to-play poker games, is now available to play on Steam with full crossplay functionality. Launched in 2007 as Zynga's first-ever game, the legendary title is raising the stakes as the label's first game to launch on Steam. With one account, players can now move freely between mobile (iOS and Android), web browsers at z

    8/15/25 9:00:00 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

    PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be discussed with global health authorities for potential regulatory filings Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the Phase 3 EV-303 clinical trial (also known as KEYNOTE-905). The EV-303 study is evaluating PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor, as neoadju

    8/12/25 5:30:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date July 31, 2025

    NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of July 31, 2025, short interest in 3,285 Nasdaq Global MarketSM securities totaled 13,683,072,188 shares compared with 13,792,841,090 shares in 3,260 Global Market issues reported for the prior settlement date of July 15, 2025. The mid-July short interest represents 2.15 days compared with 2.37 days for the prior reporting period. Short interest in 1,658 securities on The Nasdaq Capital MarketSM totaled 2,910,549,464 shares at the end of the settlement date of July 31, 2025, compared with 2,853,251,720 shares in 1,647 securities for the previous reporting period. This represents a 1.00 day average daily volume;

    8/11/25 4:05:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    11/14/24 4:29:16 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    10/31/24 4:06:54 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Take-Two with a new price target

    Wells Fargo initiated coverage of Take-Two with a rating of Overweight and set a new price target of $265.00

    7/28/25 9:00:36 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    NASDAQ upgraded by UBS with a new price target

    UBS upgraded NASDAQ from Neutral to Buy and set a new price target of $115.00

    7/25/25 8:52:40 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Cantor Fitzgerald initiated coverage on Pfizer with a new price target

    Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

    4/22/25 8:03:45 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Leadership Updates

    Live Leadership Updates

    View All

    Mafia: The Old Country Now Available Worldwide

    Dive into the roots of organized crime in 1900s Sicily with a compelling new cast of characters today Today, 2K and Hangar 13 announced that Mafia: The Old Country, the highly anticipated latest installment in the acclaimed Mafia franchise, is now available worldwide for PlayStation®5 (PS5®), Xbox Series X|S, and PC via Steam. The story will take players back in time to 1900s Sicily, which has been painstakingly created with the utmost authenticity and detail. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250808972468/en/Today, 2K and Hangar 13 announced that Mafia: The Old Country, the highly anticipated latest installment i

    8/8/25 10:00:00 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Thomson Reuters Corp to Join the Nasdaq-100 Index® Beginning July 28, 2025

    NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Thomson Reuters Corp (NASDAQ:TRI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX®) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 28, 2025. Thomson Reuters Corp will replace ANSYS, Inc. (NASDAQ:ANSS) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. ANSYS, Inc. will also be removed from the Nasdaq-100 Tech Sector™ Index (NASDAQ:NDXT), the Nasdaq-100 Technology Sector Market-Cap Weighted™ Index (NDXTMC™), the Nasdaq-100 Technology Sector Adjusted Market-Cap Weighted™ Index (NDXT10™), the Nasdaq-100 ESG™ Index (NASDAQ:ND

    7/18/25 8:00:00 PM ET
    $ANSS
    $NDAQ
    $TRI
    Computer Software: Prepackaged Software
    Technology
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Welcomes 142 IPOs in the First Half of 2025

    Highest volume of listings and capital raise in the first half of the year since 2021 Maintained leadership in switches - crossed $3 trillion in market value transferred since 2005 Driving smart policy reforms to improve regulatory processes for public companies NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) announced today that in the first half of 2025, it welcomed 142 listings (IPOs), raising a total of $19.2 billion. A total of 83 operating companies and 59 SPACs listed on Nasdaq during the first six months of 2025, representing an 86% win-rate of Nasdaq-eligible listings in the U.S. market, and extending Nasdaq's leadership to 46 consecutive quarters. In add

    7/1/25 8:05:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Financials

    Live finance-specific insights

    View All

    Take-Two Interactive Software, Inc. Reports Results for Fiscal First Quarter 2026

    Company raises fiscal year 2026 outlook Fiscal first quarter Net Bookings were $1.42 billion, above Company's guidance range Net Bookings for fiscal year 2026 are now expected to range from $6.05 to $6.15 billion Take-Two Interactive Software, Inc. (NASDAQ:TTWO) today reported results for the first quarter of its fiscal year 2026, ended June 30, 2025. For further information, please see the first quarter fiscal 2026 results slide deck posted to the Company's investor relations website at take2games.com/ir. CEO Comments Strauss Zelnick, Chairman and CEO of Take-Two Interactive stated: "Our outstanding first quarter results reflect ongoing demand for our core franchises and the incr

    8/7/25 4:05:00 PM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

    Strengthened Commercial Execution Driving Topline Growth Continued Progress Across R&D Pipeline Expanded Programs On Track to Deliver Net Cost Savings Targets Pfizer Inc. (NYSE:PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1) for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "Pfizer had another strong quarter of focused execution and we're pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen our company for the future and we're confident in our ability to cre

    8/5/25 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasdaq Announces Quarterly Dividend of $0.27 Per Share

    NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (NASDAQ:NDAQ) has declared a regular quarterly dividend of $0.27 per share on the company's outstanding common stock. The dividend is payable on September 26, 2025 to shareholders of record at the close of business on September 12, 2025. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets an

    7/24/25 7:01:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/12/24 3:53:01 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Nasdaq Inc.

    SC 13G - NASDAQ, INC. (0001120193) (Subject)

    11/8/24 10:52:39 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/4/24 1:18:47 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance